The combination of agonistic anti-CD40 with antiangiogenic antibodies targeting two pro-angiogenic factors, VEGF-A and ANG2, facilitated tumor rejection and induced immune response in murine tumor models of colon cancer and melanoma [239]. This evidence concerns the gene ANGPT2 and melanoma.